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Bacteriocins are a kind of ribosomal synthesized antimicrobial peptides produced by
bacteria, which can kill or inhibit bacterial strains closely-related or non-related to produced
bacteria, but will not harm the bacteria themselves by specific immunity proteins.
Bacteriocins become one of the weapons against microorganisms due to the specific
characteristics of large diversity of structure and function, natural resource, and being
stable to heat. Many recent studies have purified and identified bacteriocins for application
in food technology, which aims to extend food preservation time, treat pathogen disease
and cancer therapy, and maintain human health. Therefore, bacteriocins may become a
potential drug candidate for replacing antibiotics in order to treat multiple drugs resistance
pathogens in the future. This review article summarizes different types of bacteriocins
from bacteria. The latter half of this review focuses on the potential applications in food
science and pharmaceutical industry.
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INTRODUCTION
There are many antibacterial substances produced by ani-
mals, plants, insects, and bacteria, such as hydrogen peroxide,
fatty acids, organic acids, ethanol, antibiotics, and bacteriocins.
Antimicrobial peptides (AMPs) or proteins produced by bacteria
are categorized as bacteriocins. Scant nutrients in the environ-
ment trigger microbial production of a variety of bacteriocins for
competition of space and resources. Bacteriocins are abundant,
have large diversity, and the genes encode ribosomally synthesized
antimicrobial peptides or proteins, which kill other related (nar-
row spectrum) or non-related (broad spectrum) microbiotas as
one of the inherent defense system weapons of bacteria (Figure 1)
(Cotter et al., 2005). More than 99% of bacteria can produce at
least one bacteriocin, most of which are not identified (Riley and
Wertz, 2002). The killing ability of bacteriocins is considered a
successful strategy for maintaining population and reducing the
numbers of competitors to obtainmore nutrients and living space
in environments. Unlike most antibiotics, which are secondary
metabolites, bacteriocins are ribosomally synthesized and sensi-
tive to proteases while generally harmless to the human body and
surrounding environment.
Modern society is more conscious of the importance of food
safety, as many of the chemical additives used in food may elicit
toxic concern; therefore, it is beneficial to claim natural resources
and health benefits of diets. The health benefits of natural foods
without chemical additives have become more popular; how-
ever, most commercially available preservatives and antibiotics
are produced by chemical synthesis, and long-term consump-
tion of such products can affect human health as they reduce
the counts of bacteria in the gut. Moreover, the use of antibiotics
or residues in food is illegal. Unlike chemical preservatives and
antibiotics, “generally recognized as safe” (GRAS) bacteriocins,
such as nisin, promise safe use as a food preservative in vegeta-
bles, dairy, cheese, meats, and other food products, as they inhibit
microorganisms contamination during the production process
(Deegan et al., 2006; Settanni and Corsetti, 2008).
This review focuses on the classification of bacteriocins from
Gram-negative and Gram-positive bacteria. The application of
bacteriocin-producing bacteria and bacteriocins from natural
resources for human life is also elucidated upon in the report.
CLASSIFICATION OF BACTERIOCINS
BACTERIOCINS FROM GRAM-NEGATIVE BACTERIA
Colicins
Colicins are antibacterial proteins produced by bacteria, which
can kill bacterial strains closely related to a produced species, in
order to reduce environmental competitors for acquiring nutri-
ents and living space. Colicins are organized in three specific
domains, an amino-terminal translocation (T) domain, which
is implicated in the transfer across the outer membrane via
the translocator protein; a central receptor-binding (R) domain,
which is bound with a bacterial outer membrane receptor; and
a carboxy-terminal cytotoxic (C) domain, which has antibacte-
rial activity (Cascales et al., 2007; Kleanthous, 2010). In order to
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FIGURE 1 | Bacteriocins function as a natural bacterial immune weapon
system. Gram-positive and Gram-negative can produce many kinds of
bacteriocins that allow bacteriocin-producing bacteria to have the ability to
inhibit the growth of sensitive bacteria. (A) General process of bacteriocins
production and antibacterial functions. Bacteriocins are proteins or peptides
synthesized by the ribosomal. When released by bacteriocin-producing
bacteria, it can become combined with the corresponding receptor on the
surface of the sensitive bacteria to kill the bacteria. The sensitive bactericidal
mechanisms include the pore-forming type, a nuclease type with DNase and
RNase function, and peptidoglycanase type etc. The structure of an unmodified
bacteriocin peptide of small molecular weight is subtilisin A (PDB cord 1PXQ).
The structure of the modified bacteriocin peptide of small molecular weight is
bacteriocin AS-48 (PDB cord 1O83), and the colicin protein structure is colicin
Ia (PDB cord 1CII). These structural diagrams are taken from the website of a
protein data bank (PDB). (B) When the bacteriocin-producing strains are
growing on sensitive bacteria LB soft agar, an inhibition zone will be produced
around the bacteriocin-producing strains (right colony). However, there is no
inhibition zone around bacteriocin non-producing strains (left colony).
avoid poisoning by self-produced colicins, specificity immunity
proteins will be simultaneously produced to inactivate colicins
(Kleanthous, 2010). When a bacterial outer membrane surface
has the colicins recognition receptors protein and the translo-
cators protein system, the colicins are transported into the bac-
teria, which kills it, and are known as sensitive strains. For a
particular colicin, non-receptor protein bacteria are classified
as resistant strains. Bacteria with a deficiency of translocator
protein system are classified as tolerant strains, which produce
immunity proteins are classified as immune strains. Resistant,
tolerant, and immune strains of bacteria would not be killed by
corresponding colicins. There are many colicins found in suc-
cession, most of which are encoded on plasmids, while few are
located in chromosomes. A typical colicin gene cluster encodes
the toxin protein, immunity protein, and lysis gene (Guasch et al.,
1995; Kleanthous, 2010). The lysis protein, known as bacteriocin
release protein (BRP), can induce the release of colicins from
bacteria.
According to translocation across the outer membrane
(translocator) system, colicins are categorized into two groups:
groups A and B (Table 1). Group A colicins use the Tol pro-
tein system (Tol system) to penetrate the outer membrane
of sensitive bacteria, for example: colicins E1 to E9, colicin
A, K, N. . . Group B barteriocins use the Ton system (Ton
system) to penetrate the outer membrane of sensitive bacte-
ria, for example: colicin 5, 10, B, D, M, V, Ia, Ib. . . (Dimov
et al., 2005; Kleanthous, 2010). In the general, group A col-
icins are encoded on small plasmids with a lysis gene and
can be released out of the bacteria, while group B colicins are
encoded on large plasmids without a lysis gene (Cascales et al.,
2007).
When colicins enter the target cell, they can be divided
into three categories based on bactericidal mechanisms: (1)
Pore-forming type colicins: the formation of pores or chan-
nels in the inner-membrane cause leakage of cytoplasmic
compounds, destruct electrochemical gradient, ion loss, and
cell death. These include colicin A, B, E1, Ia, Ib, K, and
N; (2) Nuclease type colicins: colicins containing DNase,
16S rRNase, and tRNase to non-specifically digest DNA
and RNA of bacteria. These include colicin E2 to E9;
(3) Peptidoglycanase type colicins: these proteins can digest
the peptidoglycan precursor, leading to an inability to syn-
thesize peptidoglycan and bacterial death (Cascales et al.,
2007).
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Table 1 | Classification of colicins by different translocators system: Tol- and Ton-dependent in the E. coli.
Colicins Antibacterial activity Receptor Translocators Molecular
weight (Da)
Producing strain References
GROUP A
A Pore-forming BtuB OmpF, TolABQR 62989 Citrobacter freudii Varenne et al., 1981; Morlon
et al., 1983
E1 Pore-forming BtuB TolC, TolAQ 57279 Escherichia coli Yamada et al., 1982
K Pore-forming Tsx OmpAF, TolABQR 59611 Escherichia coli Pilsl and Braun, 1995a,b,c
N Pore-forming OmpF OmpF, TolAQR 41696 Escherichia coli Pugsley, 1987
S4 Pore-forming OmpW OmpF, TolABQR 54085 Escherichia coli Pilsl et al., 1999
U Pore-forming OmpA OmpF, TolABQR 66289 Shigella boydii Smajs et al., 1997
28b Pore-forming OmpA OmpF, TolABQR 47505 Serratia marcescens Guasch et al., 1995
GenBank: CAA44310.1
E2 DNase BtuB OmpF, TolABQR 61561 Escherichia coli
Shigella sonnei
Herschman and Helinski,
1967; Cursino et al., 2002
E7 DNase BtuB OmpF, TolABQR 61349 Escherichia coli Chak et al., 1991; Cursino
et al., 2002
E8 DNase BtuB OmpF, TolABQR ∼70000 Escherichia coli Toba et al., 1988
E9 DNase BtuB OmpF, TolABQR 61587 Escherichia coli Chak et al., 1991; Macdonald
et al., 2004
E3 16S rRNase BtuB OmpF, TolABQR 57960 Escherichia coli Herschman and Helinski,
1967; Cursino et al., 2002
E4 16S rRNase BtuB OmpF, TolABQR ND Escherichia coli Males and Stocker, 1982
E6 16S rRNase BtuB OmpF, TolABQR 58011 Escherichia coli Akutsu et al., 1989; Cursino
et al., 2002
DF13 16S rRNase IutA OmpF, TolAQR 59293 Escherichia coli van den Elzen et al., 1983
E5 tRNase BtuB OmpF, TolABQR 58254 Escherichia coli
Shigella sonnei
Males and Stocker, 1982
GenBank: KF925332.1
GROUP B
B Pore-forming FepA TonB-ExbBD 54742 Escherichia coli Schramm et al., 1987
Ia Pore-forming Cir TonB-ExbBD 69429 Escherichia coli Konisky and Richards, 1970
GenBank: AAA23182.2
Ib Pore-forming Cir TonB-ExbBD 69923 Escherichia coli
Shigella sonnei
Konisky and Richards, 1970
GenBank: AAA23188.1
5 Pore-forming Tsx TolC, TonB-ExbBD 53137 Escherichia coli Pilsl and Braun, 1995a
10 Pore-forming Tsx TolC, TonB-ExbBD 53342 Escherichia coli Pilsl and Braun, 1995b
D tRNase FepA TonB-ExbBD 74683 Escherichia coli Roos et al., 1989
M Peptidoglycanase FhuA TonB-ExbBD 29453 Escherichia coli Kock et al., 1987
ND, not determined.
Microcins
Microcins are low molecular weight ribosomal synthesized
hydrophobic antimicrobial peptides (<10 kDa), which is dis-
tinguished by 25–80 kDa high molecular weight colicins pro-
tein. Microcins are produced as precursor peptides, including
N-terminal leader peptide and core peptides. Microcin pre-
cursor peptides may or may not undergo a post-translational
modification process in the course of maturation to an
active microcin. Microcins are predominantly produced by
Enterobacteriaceae showing great tolerance to heat, extreme
pH, and proteases (Rebuffat, 2012). The bactericidal mech-
anisms of microcins are diverse, including the pore-forming
type, the nuclease type, such as DNase and RNase func-
tions, and inhibitors of protein synthesis or DNA replica-
tion. No microcin genes have a corresponding lysis gene,
and microcins are secreted outside the bacteria through the
Type I ABC (ATP binding cassette) transporter secretion system,
which is composed of a number of proteins (Duquesne et al.,
2007).
Microcins are classified as two categories according to molec-
ular masses, disulfide bonds in structure, and post-translational
modifications (Table 2). Class I microcins, such as microcin B17,
C7-C51, D93, and J25 are of lowmolecular weight (<5 kDa) post-
translationally modified peptides. The molecular weight of class
II microcins are larger (5–10 kDa) than that of class I microcins.
Class II microcins can be further divided into two subclasses,
including class IIa and IIb. Class IIa microcins, such as microcin
L, V, and N require three different genes to synthesize and assem-
ble functional peptides. Class IIb microcins, such as microcin
E492, M, and H47, are linear peptides with or without post-
translational modifications at the C-terminal (Severinov et al.,
2007).
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Table 2 | Classification scheme for gram-negative microcins.
Classification Characteristics Microcins Molecular weight (Da) Producing strain References
Class I Low molecular weight peptides
(<5 kDa), post-translationally modified
B17 3094 Escherichia coli Collin et al., 2013
C7/C51 1177 Escherichia coli Severinov et al., 2007
D93 <1000 Escherichia coli Martinez and Perez-Diaz,
1986
J25 2107 Escherichia coli Wilson et al., 2003
Class II Larger (5–10 kDa) peptides, with or
without post-translational
modifications
class IIa Required more than one genes to
synthesize and assemble functional
peptides
L 8884 Escherichia coli Pons et al., 2004
V 8741 Escherichia coli Fath et al., 1994
N/24 7274 Escherichia coli Corsini et al., 2010
class IIb Linear peptides with post-translational
modifications or not at C-terminal
E492 7886 Klebsiella pneumoniae Pons et al., 2002
M 7284 Escherichia coli Vassiliadis et al., 2010
H47 4865 Escherichia coli Vassiliadis et al., 2010
Bacteriocins from gram-positive bacteria
Unlike colicins from Gram-negative bacteria, which are plasmid
or chromosome encoded 25–80 kDa proteins, the Gram-positive
bacteria bacteriocins exert similar characteristics to microsins.
These gene-encoded bacteriocins are low molecular weight
antimicrobial peptides with less than 60 amino acids. In Gram-
positive bacteria, lactic acid bacteria (LAB) are the typical bacteria
producing a variety of bacteriocins of different sizes, structures,
physicochemical properties, and inhibitory spectrum. Due to the
large diversity of bacteriocins, some investigations show different
ways to classify bacteriocins from Gram-positive bacteria (Dimov
et al., 2005; Cotter et al., 2013). The Gram-positive bacteriocins
are generally divided into class I (modified peptides, lantibiotics),
class II (unmodified peptides, non-lanthionine), and class III
(large proteins, heat unstable) (Table 3).
Class I peptides are post-translationally modified bacteriocins
or lantibiotics with less than 28 amino acids small membrane-
active peptides (<5 kDa), linear or globular peptides which con-
tain lanthionine, β-methyl lanthionine, and dehydrated amino
acids. Linear structure peptides are membrane disrupting mode
of action, and globular structure peptides with cellular enzymatic
reaction. Class I bacteriocins are further subdivided into lantibi-
otics, such as linear peptide nisin and globular peptidemersacidin
(Chatterjee et al., 1992), labyrinthopeptins, such as globular pep-
tide labyrinthopeptin A2 (Meindl et al., 2010), and sactibiotics,
such as globular peptide subtilosin A (Kawulka et al., 2004).
Class II bacteriocins are 30–60 amino acids (<10 kDa), which
always exhibit the unique properties of heat tolerance, unmod-
ified non-lanthionine, and positive charge. The class II bacteri-
ocins are subdivided into five sub-classes by Cotter et al. (2013).
Class IIa bacteriocins are Listeria-active peptides with a consen-
sus amino acid sequence of YGNGVXaaC in the N-terminal, and
include pediocin PA-1 (Henderson et al., 1992) and carnobacte-
riocin X (Tulini et al., 2014). Class IIb bacteriocins require two
different unmodified peptides for forming a fully active poration
complex, such as lactacin F (Allison et al., 1994) and ABP-118
(Flynn et al., 2002). Class IIc bacteriocins are circular peptide
bacteriocins, such as carnocyclin A (Gong et al., 2009; Martin-
Visscher et al., 2009), and enterocin AS-48 (Martínez-Bueno
et al., 1994). Class IId bacteriocins are linear, non-pediocin-
like, single-peptide bacteriocins, including epidermicin NI01
(Sandiford and Upton, 2012) and lactococcin A (Holo et al.,
1991). Class IIe bacteriocins are non-ribosomal siderophore-type
post-translation modification at the serine-rich carboxy-terminal
region, such as microcin E492 (de Lorenzo and Pugsley, 1985). As
microcin E492 was isolated from Klebsiella pneumonia, which is
not a Gram-positive bacteria, the class IIe bacteriocins should be
categorized to microcins of Gram-negative bacteria.
Class III bacteriocins are large molecular weight (>30 kDa),
heat unstable proteins. Class III can be further subdivided into
two distinct groups. Group A bacteriocins are the bacteriolytic
enzymes which killing the sensitive strains by lysis of the cell well,
such as Enterolisin A (Nilsen et al., 2003). Group B bacteriocins
are non-lytic proteins such as Caseicin 80 (Müller and Radler,
1993) and Helveticin J (Joerger and Klaenhammer, 1986).
POTENTIAL APPLICATIONS OF BACTERIOCINS IN FOOD
SCIENCE, PHARMACEUTICS, AND CLINICAL MEDICINE
Bacteriocins are now widely used in food science to extend
food preservation duration (Ghrairi et al., 2012), which inhibit
pathogen infection of animal diseases (van Heel et al., 2011),
and pharmaceutical industry andmedical society to treatment for
malignant cancers (Figure 2) (Lancaster et al., 2007).
The first bacteriocin was discovered by Gratia (1925), and in
recent years, many bacteriocins are successively identified by sci-
entists. Bacteriocins are considered as a natural product because
they are the peptides or proteins produced by bacteria present
in many fermented or non-fermented foods since ancient times.
Many microorganisms, such as bacteriocin producing LAB, are
used to start cultures or co-cultures in food production processes
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Table 3 | Classification scheme for gram-positive bacteriocins.
Classification/features Bacteriocins Molecular weight (Da) Producing strain References
CLASS I
The bacteriocins are
post-translationally modified,
linear or globular peptides
containing lanthionine, β-methyl
lanthionine and dehydrated amino
acids
Nisin A 3352 Lactococcus lactis subsp.
lactic
Field et al., 2012
Nisin U 3029 Streptococcus uberis Wirawan et al., 2006
Nisin Z 3493 Lactococcus lactis subsp.
lactic
Mulders et al., 1991
Mersacidin 1824 Bacillus sp.Y85,54728 Chatterjee et al., 1992
Labyrinthopeptin A2 1922 Actinomadura sp. Meindl et al., 2010
subtilosin A 3399 Bacillus subtilis 168 Babasaki et al., 1985
CLASS II
Heat stable, unmodified,
non-lanthionine-containing
bacteriocins, heterogeneous class
of small peptides
Class IIa (pediocin PA-1like
bacteriocins)
pediocin PA-1 4629 Pediococcus acidilactici
PAC-1.0
Henderson et al., 1992
carnobacteriocin X 3602 Carnobacterium
maltaromaticum C2
Tulini et al., 2014
Class IIb (composed of two
peptides)
lactacin F 4755 Lactobacillus spp. Fremaux et al., 1993
ABP-118 4096 Lactobacillus salivarius subsp.
salivarius UCC118
Flynn et al., 2002
Class IIc (circular peptide) carnocyclin A 5862 Carnobacterium
maltaromaticum UAL307
Martin-Visscher et al., 2008
enterocin AS-48 7149 Enterococcus faecalis Samyn et al., 1994
Class IId (linear, non-pediocin like,
single-peptide)
epidermicin NI01 6074 Staphylococcus epidermidis Sandiford and Upton, 2012
lactococcin A 5778 Lactococcus lactis subsp.
Cremoris
Holo et al., 1991
CLASS III
Large, heat unstable proteins Caseicin 80 ∼42000 Lactobacillus casei B80 Muller and Radler, 1993
Enterolisin A 34501 Enterococcus faecalis LMG
2333
Nilsen et al., 2003
Helveticin J 37511 Lactobacillus helveticus 481 Joerger and Klaenhammer,
1990
for increasing flavor and prolonging shelf-life. In addition, many
bacteriocin producing bacteria are isolated from foods and their
raw materials (Settanni and Corsetti, 2008).
PROBIOTICS
The term “probiotic” is derived from the Greek pro bios, meaning
“for life” or “in support of life,” which was first used by Lilly and
Stillwell (1965). The probiotic is generally considered to promote
the balance of intestinal microbiota and increase health bene-
fits. The World Health Organization (WHO) defines probiotics
as, “Live microorganisms which, when administrated in adequate
amounts, confer a health benefit on the host” (Dobson et al.,
2012). The characteristics of probiotics should include: a group
of strains beneficial to the host animal that can stably survive
and have metabolic activity in the intestinal environment, and
being non-pathogenic and non-toxic, remain stable and viable for
long periods of storage and harsh conditions (Fuller, 1989). There
are many ways for probiotics to control intestinal pathogens.
Probiotics demonstrate the capabilities of antimicrobial sub-
stance production, competitive exclusion of pathogen binding,
competition for nutrients, and modulation of the immune sys-
tem (FAO/WHO, 2001). Many antibacterial substances, such as
bacteriocins, short chain fatty acids, and hydrogen peroxide, are
produced by probiotics for inhibiting gastrointestinal microor-
ganisms or pathogens. Dobson et al. (2012) considered that
bacteriocins are one of the traits of probiotics. Currently many
probiotics are used in daily life, including LAB, non-pathogenic
E. coli, bacilli, and yeasts.
Purified bacteriocins, or bacteriocin producing probiotics, can
reduce the number of pathogens or change the composition of
intestinal microbiota in animal models, such as mice, chick-
ens, and pigs. Bernbom et al. (2006) report the ability of pure
nisin, nisin-producing Lactococcus lactis strain CHCC5826 and
non-nisin-producing Lactococcus lactis strain CHCH2862, could
affect the composition of intestinal microbiota in human flora-
associated rats. They found that the number of Bifidobacterium
in the feces of rats fed with nisin-producing and non-nisin-
producing Lactococcus lactis for 8 days significantly increased,
while the number of enterococci/streptococci in duodenum,
ileum, cecum, and the colon were reduced. However, the above
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FIGURE 2 | Bacteriocin-producing strains and purified bacteriocins can
be applied to food, animals, and medicine. If bacteriocin-producing
strains are applied through start culture or co-culture in food, it can extend
the preservation of food. Probiotics produced by bacteriocins can balance
the bacteria in the digestive tract to reduce gastrointestinal diseases.
Purified bacteriocins can be added directly to foods as a natural
preservative. Bacteriocins can be added to animal feed as an anti-pathogen
additive to protect livestock against pathogen damage. The bacteriocins
used in medicine can improve the quality of human life. Bacteriocins have
the potential to replace antibiotics as an antibacterial drug, and are a novel
anti-cancer drug.
effect was not found after feeding of purified nisin. Lactococcus
lactismay affect the intestinal microbiota through competition of
nutrients or adhesion sites. Therefore, the effect of changes in the
composition of intestinal microbiota may be not related to the
presence of nisin in Lactococcus lactis. Cursino et al. (2006) indi-
cated that colicin Ib, E1, and microcin C7, as derived from E. coli
strain H22, possess the ability to inhibit the growth of pathogenic
or non-pathogenic bacteria, including Enterobacter, Escherichia,
Klebsiella, Morganella, Salmonella, Shigella, and Yersinia. In a
germ-free mouse model, E. coli strain H22 showed the ability to
reduce the population of Shigella flexneri 4 to undetectable lev-
els in feces after a 6-day oral inoculation (Cursino et al., 2006).
The results suggested that E. coli strain H22, and other multiple
bacteriocin producing strains, had potential to be employed as a
probiotic for livestock and humans. Corr et al. (2007) demon-
strated that the human origin probiotic strains Lactobacillus
salivarius UCC118 produced bacteriocin Abp118 for inhibiting
infection with foodborne pathogen Listeria monocytogenes in
mice. The bacteriocin Abp118 mutant strain UCC118abp118
failed to protect mice against infection by Listeria monocytogenes.
Riboulet-Bisson et al. (2012) also demonstrated that bacteriocins
of UCC118 were one of the points in changing the composition
of microbiota in the mice and pig models. Millette et al. (2008)
isolated two bacteriocin-producing LAB, Lactococcus lactisMM19
and Pediococcus acidilacticiMM33, from human feces, and found
the ability of LAB to reduce the numbers of vancomycin-resistant
Enterococci (VRE) in the C57BL/6 mice model. Nisin Z and
pediocin PA-1/AcH were produced by Lactococcus lactis MM19
and Pediococcus acidilactici MM33, respectively, which showed
strong activity against clinical VRE isolate. The results revealed
that Lactococcus lactis and non-pediocin PA-1/AcH producing
mutant Pediococcus acidilacticiMM33A had the ability to increase
the total LAB and anaerobes populations, while Pediococcus acidi-
lactici MM33 decreased the Enterobacteriaceae populations in
healthy mice feces. Moreover, after feeding MM19 or MM33 for
3 days, the VRE populations in feces were respectively reduced
to 2.50 and 1.85 log10 CFU/g than PBS control. A similar study
(Dabour et al., 2009) demonstrated that pediocin PA-1 produc-
ing probiotic Pediococcus acidilacticiUL5 had the ability to inhibit
Listeria monocytogenes in vitro. However, Pediococcus acidilactici
UL5 did not reduce the population of Listeria monocytogenes
in the mouse intestinal, and was not detectable in fecal sam-
ples. Pediococcus acidilactici UL5 did not protect from infection
of Listeria monocytogenes, which was due to the failure to com-
pete with other intestinal microbes or inhibit the production
of pediocin PA-1 by other microbial in the intestine. There is
another ideal situation for artificially establishing probiotic, by
transforming a bacteriocin gene into an E. coli strain. The ben-
efits to humans by the more powerful probiotics can be produced
using genetic engineering techniques. Gillor et al. (2009) utilized
six different bacteriocin-encoding plasmids, including colicin A,
E1, E2, E7, K, and N, in order to transform into the E. coli strain
BZB1011. Four-week-old CD-1 mice were inoculated with the
BZB1011 control strain, or one of the six colicinogenic BZB1011
strains. The fecal bacteria were monitored for 112 days. After 112
days incubation, the density of colicinogenicity BZB1011 in the
feces was significantly higher than that of control BZB1011. The
results suggest that colicin expression is helpful to increase E. coli
colonization in the mouse gastrointestinal tract.
FOOD TECHNOLOGY
In order to extend shelf-life, antibiotics or food preservative are
incorporated (e.g., nitrite and sulfur dioxide) into foods to delay
microbial growth and possible corruption. However, most com-
mercial preservatives are developed via chemical synthesis, and
long-term consumption of the synthetic preservatives may have
an adverse impact on the human body. Moreover, it is illegal
to use antibiotics in food products. The bacteriocins produced
by Gram-positive or Gram-negative bacteria are gene encoded
peptides or proteins, which are suitable as natural preservatives
in food products. Due to the sensitivity of bacteriocins to some
proteases, harmless bacteriocins are possibly digested, thus, un-
functional small peptides and amino acids are bacteriocin-loaded
foods digested in the gastrointestinal tract (Cleveland et al.,
2001; Bernbom et al., 2006). Thus, bacteriocins are considered
as basically safe food additives after intake by the gastrointestinal
system.
Bacteriocins are natural food additives due to the bacteriocin
producing bacteria presence in many types of foods since ancient
times, such as cheeses, yogurts, and Portuguese fermented meat
(Yang et al., 2012; Todorov et al., 2014). In food technology, nisin
is produced by Lactococcus lactis and was the first antibacterial
peptide found in LAB (Rogers, 1928). It is also a commercial
bacteriocin used as a food preservative against contamination by
microorganism, which is marketed as Nisaplin®. It is the only
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bacteriocin approved for utilization as a preservative in many
foods by the U.S. Food and Drug Administration (USFDA),
and licensed as a food additive in over 45 countries (Settanni
and Corsetti, 2008). Another commercially available bacteriocin
is pediocin PA-1, marketed as Alta® 2341, which inhibits the
growth of Listeria monocytogenes in meat products (Settanni
and Corsetti, 2008). In many food products, such as traditional
European cheeses, the milk used in the manufacturing process
is easily contaminated with animal excrement. The bacteriocino-
genic Enterococci as starter cultures or co-cultures can be used
for reducing microbiota contamination (Foulquié Moreno et al.,
2006). Settanni and Corsetti (2008) reviewed bacteriocinogenic
LAB strains as a co-culture, protective, or starter cultures in
fermented and non-fermented vegetables, such as olives, sour-
dough, miso, sauerkrauts, refrigerated pickles, and mungbean
sprouts. Moreover, they introduced bacteriocins as foods addi-
tives, such as nisin, which is used in kimchi, mashed potatoes,
and fresh-cut products. Enterocin AS-48 is used in cider, fruit
and vegetable juices, and canned vegetables for contamination
inhibition. Enterocin CCM4231 and EJ97 are used in soy milk
and zucchini purée for suppression of contamination, respectively
(Settanni and Corsetti, 2008).
TREATMENT OF PATHOGEN-ASSOCIATED DISEASES
Since the first antibiotic penicillin was discovered in 1928 by
Alexander Fleming, many discovered antibiotics are applied to
treat pathogens. Antibiotics were first approved by USFDA in
1951, and used in animal feed, which significantly reduced the
number of deaths due to bacterial infection cases. However,
the problem with multiple drug resistance pathogens has
become increasingly serious, due to concerns regarding the
abuse of antibiotics (Joerger, 2003). Bacteriocins are reported
to inhibit important animal and plant pathogens, such as
Shiga toxin-producing E. coli (STEC), enterotoxigenic E. coli
(ETEC), methicillin-resistant Staphylococcus aureus (MRSA),
VRE, Agrobacterium, and Brenneria spp. (Grinter et al., 2012;
Cotter et al., 2013). The bactericidal mechanism of bacteriocins
are mainly located in the receptor-binding of bacteria surfaces,
and then through the membrane, which causes bacteria cytotox-
icity. In addition, bacteriocins are low-toxic peptides or proteins
sensitive to proteases, such as trypsin and pepsin (Cleveland et al.,
2001).
Jordi et al. (2001) found that 20 kinds of E. coli could express
colicin, which inhibited five kinds of Shiga toxin-producing E. coli
(O26, O111, O128, O145, and O157: H7). These E. coli can
cause diarrhea and hemolytic uremic syndrome in humans. In
a simulated cattle rumen environment, colicin E1, E4, E8-J, K,
and S4 producing E. coli can significantly inhibit the growth
of STEC. Stahl et al. (2004) utilized purified colicin E1 and
colicin N for effective activity against enterotoxigenic E. coli
pathogens F4 (K88) and F18 in vitro, which caused post-weaning
diarrhea in piglets. Furthermore, purified coilicin E1 proteins
were mixed with the dietary intake of young pigs. The results
showed a reduction of the incidence of post-weaning diarrhea
by F-18 positive E. coli (Cutler et al., 2007). The growth of
the piglets was thus ameliorated. Józefiak et al. (2013) used the
nisin-supplemented bird diet to feed broiler chickens, and found
a reduced number of Bacteroides and Enterobacteriacae in ileal
digesta of nisin-supplemented chickens. The action of nisin was
similar to that of salinomycin. After a 35-day growth, the aver-
age body weight gain of nisin-supplemented (2700 IU nisin/g)
chickens is 1918 g/bird, which was higher than the 1729 g of non-
nisin supplemented or the 1763 g of salinomycin-supplemented
chickens. Stern et al. (2006) reported that class II low molecule
mass bacteriocin OR-7 was purified from the Lactobacillus sali-
varius strain NRRL B-30514. This bacteriocin exhibited an
ability against human gastroenteritis pathogen Campylobacter
jejuni. OR-7 was stable when treated with lysozyme, lipase, and
heat to 90◦C, or at pH ranges from 3.0 to 9.1. The puri-
fied OR-7 was encapsulated in polyvinylpyrrolidone for chicken
feed. The populations of C. jejuni were reduced at least one
million fold over that of non-OR-7 supplemented chickens in
cecal material of OR-7-treated chickens. These results suggest
that nisin, OR-7, and other bacteriocins, illustrated potential
when applied to replace antibiotics in poultry and other animal
feeds.
CANCER THERAPY
Over the past half century, cancer has become a serious problem,
and a threat to human health. According to new information from
theWHOwebsite, there were 8.2 million people died from cancer
and 14.1 million new cancer cases worldwide in 2012, with 60%
of world’s total new annual cases occurring in Africa, Asia, and
Central and South America. Of the world’s top 10 leading causes
of death, lung cancer (2.7%, including trachea and bronchus can-
cer) was 7th and caused 1.5 million (2.7%) deaths in 2011, higher
than 1.2 million (2.2%, 9th) deaths in 2000. In the United States,
there were 1,660,290 new cancer cases, with 580,350 cancer deaths
projected to occur in 2013, pedestalling cancer as the second lead-
ing cause of death, exceeded only by heart diseases (Center, 2013;
Siegel et al., 2013).
In cancer therapy, some researches indicate that bacteriocins
show activity against tumor cells. Considering that bacteriocins
are naturally and legally added in foods, bacteriocins may be
suitable as a potential anti-tumor drug candidate. Some bacteri-
ocins, such as pore-forming colicin A and E1 inhibited the growth
of one human standard fibroblast line MRC5 and 11 human
tumor-cell lines (Chumchalová and Smarda, 2003). Contrarily,
pore-forming colicin U and RNAase activity colicin E3 did not
display this growth inhibition capability. Colicin D, E2, E3, and
pore-forming colicin A could inhibit the viability of murine
leukaemia cells P388, while pore-forming colicin E1 and colicin
E3 suppressed v-myb-transformed chicken monoblasts (Fuska
et al., 1979; Lancaster et al., 2007). Bures et al. (1986) isolated
E. coli from the feces of 77 colorectal carcinoma patients, where
32 patients (41.6%) had barteriocins-producing E. coli. In the
feces of 160 healthy people, 102 people (63.8%) had barteriocins-
producing E. coli, which also showed that colicins from bacteria
in the intestine may be one of the factors in reducing human col-
orectal carcinoma. Colicins could act as an anti-cancer drug of
moderate potential. Supplements of bacteriocin-producing pro-
biotics may be another way to prevent cancer occurrence. In a
recent study, Joo et al. (2012) found that nisin had capabilities
to prevent cancer cell growth. Three head and neck squamous
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cell carcinoma (HNSCC) 17B, HSC, and 14A were treated by
nisin at concentrations of 40 and 80μg/ml. After 24 h nisin
increased DNA fragmentation or apoptosis, arrested cell cycle
and reduced cell proliferation of HNSCC occurred. The floor-of-
mouth oral cancer xenograft mouse model was used to test the
anti- HNSCC function of nisin. A 150-mg/kg dose of nisin was
administered orally every day for 3 weeks, and tumor volumes
were significantly reduced in nisin-treated mice, as compared
with the control mice, which received only water. These results
indicated that nisin provides a safe and novel therapy for treating
HNSCC.
CONCLUSIONS AND FUTURE PERSPECTIVES
In general, the genes and immune genes of bacteriocins are
encoded on the same plasmid or in adjacent regions of a chromo-
some. The bactericins genes can enter into other bacterial cells via
conjugation (Ito et al., 2009; Burton et al., 2013). Accordingly, by
conjugation or transposon for insertion, the bacterial pathogen
can obtain some immune genes of bacteriocins. In this way, in
environment or food pathogens prevention strategies, the use
of purified bacterial peptide or protein is superior to the use
of bacteria to produce bacteriocins. In terms of disease control,
many papers report only the ability to fight pathogens of the
probiotic produced by a single or specific bacteriocin, and the
ability of the probiotic generated by a single bacteriocin to bal-
ance the bacteria strains in the intestinal tract. However, there are
many different kinds of pathogens and mutants in nature. The
specific use of a particular bacteriocin cannot eliminate all bac-
terial pathogens. Therefore, we can mix a variety of bacteriocin
proteins to make cocktail drugs for application to the preven-
tion of certain human or animal pathogens to cause death or
reduce its diffusion rate. In disease control, bacteriocin can solve
some of the most challenging problems of multi-drug resistant
pathogens.
In recent years, the increased number of multi-drug resis-
tant pathogens has become a serious problem, and finding or
developing a new generation of antimicrobial agents is becom-
ing increasingly important. Many new antibacterial substances
have also been found by scientists to replace the old antibiotics;
however, finding and identifying new antimicrobial substances
is a difficult task, and the use of biotechnology to fuse two
known bacteriocins into a new bacteriocins may be a quick fix
method. By using recombinant PCR techniques, Acuña et al.
(2012) integrated enterocin CRL35 and microcin V genes to
obtain a bacteriocins called Ent35-MccV. Ent35-MccV has bac-
tericidal capacity against clinically isolated enterohemorrhagic
E. coli and Listeria monocytogenes, as well as some Gram-positive
and Gram-negative bacteria, which are not clinically isolated.
Such a technique can crease new or multi-functional bacteriocins,
which are more powerful in functionality and germicidal range.
As a result, they can be widely used in food, animal husbandry,
and medicine.
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